Abbott Laboratories

Industry: BioTech Healthcare Major Drugs

Fortune Rank: 75

For the nine months ended 30 September 2005, Abbott Laboratories's revenue increased 16% to $16.29B. Net income from continuing operations increased 9% to 2.4B. Revenue reflects improved performance in Pharmaceutical Products Group led by HUMIRA and Abbott Diabetes Care in Medical Products Group respectively. Net income was partially offset by lower operating margin, higher research & development cost and increased selling, general & administrative cost.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. Abbott operates in four segments: Pharmaceutical Products, Diagnostic Products, Ross Products and International. The Pharmaceutical Products segment's products include a broad line of adult and pediatric pharmaceuticals (sold on the prescription or recommendation of physicians). The Diagnostic Products segment's products include diagnostic systems and tests for blood banks, hospitals, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies and consumers. The Ross Products segment's products include a broad line of pediatric and adult nutritionals. The International segment's products include a broad line of pharmaceutical, and adult and pediatric nutritional products marketed and manufactured outside the United States. Abbott also has a 50%-owned joint venture, TAP Pharmaceutical Products Inc.

Abbott Laboratories

Abbott Laboratories is a Fortune 500 company. In 2010 Abbott Laboratories was ranked number 75 on the Fortune 500 list, making it the 75th largest company in the United States when judged by revenue.

Abbott Laboratories achieved revenue of $30,764.70 million in 2010 and earned a profit of $5,745.80 million.

Abbott Laboratories' rank improves

The company ranking improved in 2010, moving up the Fortune 500 list to 75th compared to 80th in 2009. This was based on its 2009 revenue of $29,528 million (a change of 1 million compared to 2010) and profits of $4,881 million (a change of $1 million compared to 2009).

Another point of view

To many investors, profits are more important than the revenue a company earns. If the Fortune 500 was ranked by profits instead of revenue then Abbott Laboratories would be ranked 25th rather than 75th due to its profits of $5,746 in 2010.

Abbott Laboratories Revenue* Profit* Fortune Ranking

* US$ Million

USPages Latest Business News At A Glance Business Shortcuts